Combating PDAC Drug Resistance: The Role of Ref-1 Inhibitors in Accelerating Progress in Pancreatic Cancer Research

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Pancreatic Ductal Adenocarcinoma (PDAC) is a lethal cancer with limited treatment options.
• Complex tumor microenvironment (TME), heterogeneity, and drug resistance impede effective therapies.
• Redox effector 1 (Ref-1) plays a critical role in PDAC progression and resistance.

Purpose of the Study:

• To highlight the role of Ref-1 in PDAC progression and drug resistance.
• To discuss novel Ref-1 inhibitors and their therapeutic potential.
• To emphasize the use of advanced preclinical models for evaluating PDAC therapies.

Main Methods:

• Investigated Ref-1's redox regulation of transcription factors (STAT3, HIF1α, NF-κB).
• Developed and tested novel Ref-1 inhibitors in preclinical models.
• Utilized advanced models like 3D spheroids, organoids, and T-MOC systems.

Main Results:

• Ref-1 inhibitors disrupt TF activity, decreasing PDAC cell survival and proliferation.
• Inhibitors demonstrated enhanced potency and improved pharmacokinetic profiles in preclinical studies.
• Advanced models improved the prediction of therapeutic responses in PDAC.

Conclusions:

• Targeting Ref-1 offers a promising strategy to overcome PDAC drug resistance.
• Combination therapies involving Ref-1 inhibitors could disrupt multiple tumor survival mechanisms.
• Improved preclinical models are crucial for advancing PDAC treatment development.